Skip to main content
Premium Trial:

Request an Annual Quote

Atlantic Cancer Research Institute Licenses Liquid Biopsy Tech to BioVendor

NEW YORK (GenomeWeb) ­– The Atlantic Cancer Research Institute has agreed to license extracellular vesicle (EV) isolation technology to BioVendor – Laboratorní Medicína, a Czech biotechnology company developing in vitro diagnostics and research-use-only immunoassays.

The agreement gives BioVendor non-exclusive rights to use ACRI's Vn96 synthetic peptide for isolation of EVs to diagnose disease via liquid biopsy.

"The license agreement is a very important piece in our strategy to bring innovative immunoassays that target miRNA as clinically valuable biomarkers," BioVendor CEO Viktor Růžička said in a statement.

The Vn96 synthetic peptide was developed by ACRI — a private, not-for-profit research organization located at the Dr. Georges-L.-Dumont University Hospital Centre in Moncton, Canada — and New England Peptide. It allows for the capture of EVs through an interaction with canonical heat shock proteins on the exterior of exosomes and EVs, particularly from cells under stress, such as cancer cells, according to New England Peptide.